1기 자궁내막암에서 환자 보고된 하지 사지 기능 장애에 대한 감시 림프절 매핑의 영향
자궁내막암에서 보고된 하지 사지 기능 장애 환자에 대한 센티넬 림프절 매핑의 영향에 대한 3상 시험
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Standard lymph node dissection removes lymph nodes around the uterus during a hysterectomy to look for spread of cancer from the uterus to nearby lymph nodes. Sentinel lymph node mapping uses a special dye and camera to look for cancer that may have spread to nearby lymph nodes. Comparing the results of the procedures may help doctors predict the risk of long-term swelling in the legs.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
PRIMARY OBJECTIVES:
I. To compare the rates of lower extremity limb dysfunction (defined as a >= 4-point increase in Gynecologic Cancer Lymphedema Questionnaire [GCLQ] symptom score from baseline) in patients with apparent uterine confined endometrial cancer randomized to one of two lymphatic assessment strategies at time of hysterectomy:
Ia. Sentinel lymph node mapping and excision followed by side-specific lymphadenectomy on sides without a sentinel lymph node (SLN) identified according to a National Comprehensive Cancer Network (NCCN) guidelines approved algorithm (Arm 1); Ib. Sentinel lymph node mapping and excision according to an NCCN Guidelines approved algorithm followed by bilateral pelvic +/- para-aortic lymphadenectomy (Arm 2).
SECONDARY OBJECTIVE:
I. To compare changes in lower extremity limb circumference in patients with apparent uterine confined endometrial cancer randomized to one of two lymphatic assessment strategies at time of hysterectomy.
II. To validate the test characteristics of a SLN mapping algorithm including SLN detection rates, rate of perioperative complications, rate of identifying lymphatic metastases, and detection of micrometastases using pathologic ultra-staging.
EXPLORATORY OBJECTIVES:
I. To compare adjuvant therapy decisions in patients with apparent uterine confined endometrial cancer randomized to one of two lymphatic assessment strategies at time of hysterectomy.
II. To explore the impact of patient characteristics (age, body mass index [BMI], race), extent of lymph node dissection, and adjuvant therapy decisions (radiation, chemotherapy) on the development of lower extremity limb dysfunction - as well as their interaction with lymph node assessment strategies.
III. To evaluate the cost-effectiveness of SLN mapping with or without completion of lymphadenectomy for endometrial cancer.
SAFETY OBJECTIVE:
I. To compare progression free and overall survival in patients with apparent uterine confined endometrial cancer randomized to one of two lymphatic assessment strategies at time of hysterectomy.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Lymph nodes around the uterus may be removed if the mapping and excision cannot be completed. Successful mapping requires no additional removal of lymph nodes.
ARM 2: Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Additional lymph nodes around the uterus are removed per standard of care.
Patients in both arms also undergo imaging as clinically indicated and optional blood sample collection throughout the study.
After completion of study intervention, patients are followed every 3 months for one year and at 18 and 24 months.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Incheon, 대한민국, 405-760
- 모병
- Gachon University Gil Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 82-32-460-3213
-
수석 연구원:
- Kwang-Beom Lee
-
Seoul, 대한민국, 05505
- 모병
- Asan Medical Center
-
연락하다:
- Site Public Contact
- 이메일: irbksh@amc.seoul.kr
-
수석 연구원:
- Dae-Yeon Kim
-
Seoul, 대한민국, 06273
- 모병
- Gangnam Severance Hospital
-
수석 연구원:
- Jae-Hoon Kim
-
연락하다:
- Site Public Contact
- 전화번호: 82-2-2019-3600
-
Seoul, 대한민국, 07985
- 모병
- Ewha Woman's University Mokdong Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 82 2-2650-5114
-
수석 연구원:
- Yun H. Kim
-
-
Gyeongsangnam-do
-
Seoul, Gyeongsangnam-do, 대한민국, 51353
- 정지된
- Samsung Changwon Hospital
-
-
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20037
- 정지된
- George Washington University Medical Center
-
-
Florida
-
Coral Gables, Florida, 미국, 33146
- 모병
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
연락하다:
- Site Public Contact
- 전화번호: 305-243-2647
-
수석 연구원:
- Abdulrahman Sinno
-
Deerfield Beach, Florida, 미국, 33442
- 모병
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
연락하다:
- Site Public Contact
- 전화번호: 305-243-2647
-
수석 연구원:
- Abdulrahman Sinno
-
Doral, Florida, 미국, 33166
- 모병
- UM Sylvester Comprehensive Cancer Center at Doral
-
수석 연구원:
- Abdulrahman Sinno
-
연락하다:
- Site Public Contact
- 이메일: kginnity@med.miami.edu
-
Miami, Florida, 미국, 33136
- 모병
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 305-243-2647
-
수석 연구원:
- Abdulrahman Sinno
-
Miami, Florida, 미국, 33176
- 모병
- UM Sylvester Comprehensive Cancer Center at Kendall
-
연락하다:
- Site Public Contact
- 전화번호: 305-243-2647
-
수석 연구원:
- Abdulrahman Sinno
-
North Miami, Florida, 미국, 33181
- 모병
- University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
-
수석 연구원:
- Abdulrahman Sinno
-
연락하다:
- Site Public Contact
- 이메일: kginnity@med.miami.edu
-
Plantation, Florida, 미국, 33324
- 모병
- UM Sylvester Comprehensive Cancer Center at Plantation
-
연락하다:
- Site Public Contact
- 전화번호: 305-243-2647
-
수석 연구원:
- Abdulrahman Sinno
-
-
Georgia
-
Augusta, Georgia, 미국, 30912
- 모병
- Augusta University Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 706-721-2388
- 이메일: ga_cares@augusta.edu
-
수석 연구원:
- Robert V. Higgins
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Northwestern University
-
연락하다:
- Site Public Contact
- 전화번호: 312-695-1301
- 이메일: cancer@northwestern.edu
-
수석 연구원:
- Emily Hinchcliff
-
Warrenville, Illinois, 미국, 60555
- 모병
- Northwestern Medicine Cancer Center Warrenville
-
연락하다:
- Site Public Contact
- 전화번호: 630-352-5360
- 이메일: Donald.Smith3@nm.org
-
수석 연구원:
- Emily Hinchcliff
-
-
Indiana
-
Carmel, Indiana, 미국, 46032
- 모병
- IU Health North Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 317-278-5632
- 이메일: iutrials@iu.edu
-
수석 연구원:
- Jessica E. Parker
-
Indianapolis, Indiana, 미국, 46202
- 모병
- Indiana University/Melvin and Bren Simon Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 317-278-5632
- 이메일: iutrials@iu.edu
-
수석 연구원:
- Jessica E. Parker
-
-
Louisiana
-
Marrero, Louisiana, 미국, 70072
- 모병
- West Jefferson Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 504-210-3539
- 이메일: emede1@lsuhsc.edu
-
수석 연구원:
- Tara Castellano
-
Metairie, Louisiana, 미국, 70006
- 모병
- East Jefferson General Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 504-210-3539
- 이메일: emede1@lsuhsc.edu
-
수석 연구원:
- Tara Castellano
-
Metairie, Louisiana, 미국, 70006
- 모병
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
연락하다:
- Site Public Contact
- 전화번호: 504-210-3539
- 이메일: emede1@lsuhsc.edu
-
수석 연구원:
- Tara Castellano
-
New Orleans, Louisiana, 미국, 70112
- 모병
- University Medical Center New Orleans
-
연락하다:
- Site Public Contact
- 전화번호: 504-210-3539
- 이메일: emede1@lsuhsc.edu
-
수석 연구원:
- Tara Castellano
-
New Orleans, Louisiana, 미국, 70112
- 모병
- Louisiana State University Health Science Center
-
연락하다:
- Site Public Contact
- 전화번호: 504-210-3539
- 이메일: emede1@lsuhsc.edu
-
수석 연구원:
- Tara Castellano
-
-
Maryland
-
Baltimore, Maryland, 미국, 21201
- 모병
- University of Maryland/Greenebaum Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-888-8823
-
수석 연구원:
- Gautam G. Rao
-
Bel Air, Maryland, 미국, 21014
- 모병
- UM Upper Chesapeake Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 443-643-3010
-
수석 연구원:
- Gautam G. Rao
-
-
Michigan
-
Detroit, Michigan, 미국, 48201
- 모병
- Wayne State University/Karmanos Cancer Institute
-
수석 연구원:
- Robert T. Morris
-
연락하다:
- Site Public Contact
- 전화번호: 800-527-6266
- 이메일: ctoadmin@karmanos.org
-
Farmington Hills, Michigan, 미국, 48334
- 모병
- Weisberg Cancer Treatment Center
-
수석 연구원:
- Robert T. Morris
-
연락하다:
- Site Public Contact
- 전화번호: 313-576-9790
- 이메일: ctoadmin@karmanos.org
-
Flint, Michigan, 미국, 48532
- 모병
- McLaren Cancer Institute-Flint
-
수석 연구원:
- Robert T. Morris
-
연락하다:
- Site Public Contact
- 전화번호: 313-576-9790
- 이메일: ctoadmin@karmanos.org
-
-
Minnesota
-
Edina, Minnesota, 미국, 55435
- 모병
- Fairview Southdale Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- Britt K. Erickson
-
Maple Grove, Minnesota, 미국, 55369
- 모병
- Fairview Clinics and Surgery Center Maple Grove
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- Britt K. Erickson
-
Maplewood, Minnesota, 미국, 55109
- 모병
- Saint John's Hospital - Healtheast
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- Britt K. Erickson
-
Princeton, Minnesota, 미국, 55371
- 모병
- Fairview Northland Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- Britt K. Erickson
-
Saint Paul, Minnesota, 미국, 55101
- 모병
- Regions Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- Britt K. Erickson
-
Wyoming, Minnesota, 미국, 55092
- 모병
- Fairview Lakes Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 952-993-1517
- 이메일: mmcorc@healthpartners.com
-
수석 연구원:
- Britt K. Erickson
-
-
Missouri
-
Springfield, Missouri, 미국, 65804
- 모병
- Mercy Hospital Springfield
-
수석 연구원:
- Jay W. Carlson
-
연락하다:
- Site Public Contact
- 전화번호: 417-269-4520
-
-
Montana
-
Billings, Montana, 미국, 59101
- 모집하지 않고 적극적으로
- Saint Vincent Healthcare
-
Billings, Montana, 미국, 59102
- 모집하지 않고 적극적으로
- Saint Vincent Frontier Cancer Center
-
Billings, Montana, 미국, 59106
- 모집하지 않고 적극적으로
- Intermountain Health West End Clinic
-
Butte, Montana, 미국, 59701
- 모집하지 않고 적극적으로
- Saint James Community Hospital and Cancer Treatment Center
-
-
Nebraska
-
Kearney, Nebraska, 미국, 68845
- 모병
- Fred and Pamela Buffett Cancer Center - Kearney
-
연락하다:
- Site Public Contact
- 전화번호: 402-559-6941
- 이메일: unmcrsa@unmc.edu
-
수석 연구원:
- Kerry J. Rodabaugh
-
Omaha, Nebraska, 미국, 68198
- 모병
- University of Nebraska Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 402-559-6941
- 이메일: unmcrsa@unmc.edu
-
수석 연구원:
- Kerry J. Rodabaugh
-
Omaha, Nebraska, 미국, 68118
- 모병
- Nebraska Medicine-Village Pointe
-
연락하다:
- Site Public Contact
- 전화번호: 402-559-5600
-
수석 연구원:
- Kerry J. Rodabaugh
-
Omaha, Nebraska, 미국, 68124
- 모집하지 않고 적극적으로
- Alegent Health Bergan Mercy Medical Center
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89106
- 모병
- Women's Cancer Center of Nevada
-
수석 연구원:
- Nicola M. Spirtos
-
연락하다:
- Site Public Contact
- 전화번호: 702-851-4672
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- University of Oklahoma Health Sciences Center
-
연락하다:
- Site Public Contact
- 전화번호: 405-271-8777
- 이메일: ou-clinical-trials@ouhsc.edu
-
수석 연구원:
- Christina Washington
-
-
Pennsylvania
-
Bryn Mawr, Pennsylvania, 미국, 19010
- 정지된
- Bryn Mawr Hospital
-
Paoli, Pennsylvania, 미국, 19301
- 정지된
- Paoli Memorial Hospital
-
Wynnewood, Pennsylvania, 미국, 19096
- 정지된
- Lankenau Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02905
- 모병
- Women and Infants Hospital
-
수석 연구원:
- Matthew T. Oliver
-
연락하다:
- Site Public Contact
- 전화번호: 401-274-1122
-
-
Texas
-
Dallas, Texas, 미국, 75390
- 모병
- UT Southwestern/Simmons Cancer Center-Dallas
-
수석 연구원:
- Jayanthi S. Lea
-
연락하다:
- Site Public Contact
- 전화번호: 214-648-7097
- 이메일: canceranswerline@UTSouthwestern.edu
-
Dallas, Texas, 미국, 75235
- 모병
- Parkland Memorial Hospital
-
수석 연구원:
- Jayanthi S. Lea
-
연락하다:
- Site Public Contact
- 전화번호: 214-590-5582
- 이메일: canceranswerline@UTSouthwestern.edu
-
Fort Worth, Texas, 미국, 76104
- 모병
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
수석 연구원:
- Jayanthi S. Lea
-
연락하다:
- Site Public Contact
- 전화번호: 214-648-7097
- 이메일: canceranswerline@UTSouthwestern.edu
-
Houston, Texas, 미국, 77030
- 모병
- Memorial Hermann Texas Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 713-792-3245
-
수석 연구원:
- Joseph A. Lucci
-
Houston, Texas, 미국, 77030
- 모집하지 않고 적극적으로
- Houston Methodist Hospital
-
Houston, Texas, 미국, 77070
- 모집하지 않고 적극적으로
- Methodist Willowbrook Hospital
-
Houston, Texas, 미국, 77094
- 모집하지 않고 적극적으로
- Houston Methodist West Hospital
-
Richardson, Texas, 미국, 75080
- 모병
- UT Southwestern Clinical Center at Richardson/Plano
-
수석 연구원:
- Jayanthi S. Lea
-
연락하다:
- Site Public Contact
- 전화번호: 972-669-7044
- 이메일: Suzanne.cole@utsouthwestern.edu
-
Sugar Land, Texas, 미국, 77479
- 모집하지 않고 적극적으로
- Houston Methodist Sugar Land Hospital
-
The Woodlands, Texas, 미국, 77385
- 모집하지 않고 적극적으로
- Houston Methodist The Woodlands Hospital
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22908
- 모병
- University of Virginia Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 434-243-6303
- 이메일: uvacancertrials@hscmail.mcc.virginia.edu
-
수석 연구원:
- Kari L. Ring
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Histologically proven diagnosis of endometrial cancer based on endometrial sampling with a plan to undergo laparoscopic or robotic hysterectomy and lymphatic assessment as part of primary management. Biopsy must be performed within 90 days prior to registration
-
Clinical stage I endometrial cancer based on the following diagnostic workup:
- History/physical examination within 30 days prior to registration is reassuring for the absence of metastatic disease
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
-
Patients must speak English, Spanish, or Korean
Exclusion Criteria:
-
Patients whom the surgeon believes is not a candidate for pelvic lymphadenectomy due to medical comorbidities or other technical challenges (i.e. morbid obesity or prior surgery)
-
History of chemotherapy or immunotherapy for the treatment of endometrial cancer. Progestin-containing therapies such as megestrol, medroxyprogesterone, or levonorgestrel-containing intrauterine device (IUD) are acceptable
-
History of radiation to the pelvis, groin or lower extremities, or surgery to the pelvic lymph nodes or inguinal lymph nodes
-
Patients who are going to undergo another elective surgery during the same operative event as their hysterectomy (i.e., sacrocolpopexy, cholecystectomy)
-
Patients with severe, active co-morbidity defined as follows:
- History of patient or provider identified lower extremity lymphedema
- History of patient or provider identified chronic lower extremity swelling
- History of lower extremity or pelvic deep venous thromboembolism within 90 days of registration
- History of lower extremity cellulitis within 90 days of registration
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Arm 1 (sentinel lymph node mapping)
Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Lymph nodes around the uterus may be removed if the mapping and excision cannot be completed. Successful mapping requires no additional removal of lymph nodes. Patients also undergo imaging as clinically indicated and optional blood sample collection throughout the study. |
Undergo blood sample collection
다른 이름들:
Ancillary studies Undergo imaging
다른 이름들:
Undergo sentinel lymph node excision
다른 이름들:
Given via injection
다른 이름들:
Undergo minimally invasive hysterectomy
다른 이름들:
Undergo pelvic lymphadenectomy
다른 이름들:
Undergo sentinel lymph node mapping
다른 이름들:
|
|
실험적: Arm 2 (sentinel lymph node mapping, pelvic lymphadenectomy)
Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Additional lymph nodes around the uterus are removed per standard of care. Patients also undergo imaging as clinically indicated and optional blood sample collection throughout the study. |
Undergo blood sample collection
다른 이름들:
Ancillary studies Undergo imaging
다른 이름들:
Undergo sentinel lymph node excision
다른 이름들:
Given via injection
다른 이름들:
Undergo minimally invasive hysterectomy
다른 이름들:
Undergo pelvic lymphadenectomy
다른 이름들:
Undergo sentinel lymph node mapping
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of patient-reported lower extremity limb dysfunction
기간: From 18 months post-hysterectomy after undergoing lymphatic assessment to 39 months
|
The primary endpoint is the incidence of patient-reported lower extremity limb dysfunction at 18 months post-hysterectomy after undergoing lymphatic assessment according to a National Comprehensive Cancer Network guideline-based sentinel lymph node (SLN) mapping algorithm with or without completion of lymphadenectomy. The primary endpoint will be assessed using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) questionnaire. Surveys will be performed at enrollment (pre-surgery) and at 3, 6, 9, 12, and 18 months post-surgery. Patient-reported lower extremity limb dysfunction will be defined as an increase in GCLQ symptom score of at least four (4) points from baseline at any time during the 18 months follow-up. The primary null hypothesis will be evaluated with an intent-to-treat chi-squared test, adjusted for stratification factors. Proportional hazards modeling will be used to generate a hazard ratio and 95% confidence limits of Arm 1 versus Arm 2. |
From 18 months post-hysterectomy after undergoing lymphatic assessment to 39 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The incidence of lymphedema by quantifiable lower extremity limb changes
기간: From enrollment and at 3, 6, 9, 12, and 18 months after surgery
|
Patients will undergo circumferential lower extremity limb measures at three locations along each leg. Change will be estimated as measurement at baseline subtracted from measurement at follow-up. This will be assessed in both legs separately. |
From enrollment and at 3, 6, 9, 12, and 18 months after surgery
|
|
Rate of successful bilateral SLN identification
기간: At time of surgery
|
Will be assessed in both, and only as the time of surgery. |
At time of surgery
|
|
Rate of successful identification of lymph node metastasis
기간: At time of surgery
|
Will be assessed in both, and only as the time of surgery. The rate of lymph node metastasis identification during surgery will be compared between groups, with either t-tests or chi-squared tests where appropriate. |
At time of surgery
|
|
Rate of perioperative complications
기간: At time of surgery
|
Will be assessed in both arms separately, and only as the time of surgery. The rate of perioperative complications during surgery will be compared between groups, with either t-tests or chi-squared tests where appropriate. |
At time of surgery
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Adjuvant therapy decisions
기간: Up to 24 months
|
Adjuvant therapy decisions will be compared for patients according to study arm allocation after accounting for tumor characteristics, stage, and patient demographics to determine whether lymph node mapping strategies was associated with a difference in adjuvant therapy choice. |
Up to 24 months
|
|
Patient characteristic, extent of lymph node dissection, and adjuvant therapy decisions
기간: Up to 24 months
|
Patient characteristics (age, body mass index, race), extent of lymph node dissection, and adjuvant therapy decisions (radiation, chemotherapy), will be collected to determine their impact as a covariate on the development of the primary endpoint (lower extremity limb dysfunction). Models adjusting for potential confounders will be fitted and analyzed. |
Up to 24 months
|
|
Progression free survival
기간: The duration of time from study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed at 2 years after enrollment
|
This endpoint is not expected to be sufficiently powered for a definitive comparison and will therefore be treated as supportive evidence. |
The duration of time from study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed at 2 years after enrollment
|
|
Overall survival
기간: Duration of time from study entry to time of death or the date of last contact, assessed at 2 years after enrollment
|
This endpoint is not expected to be sufficiently powered for a definitive comparison and will therefore be treated as supportive evidence. |
Duration of time from study entry to time of death or the date of last contact, assessed at 2 years after enrollment
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Edward J Tanner, NRG Oncology
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- NRG-CC010
- UG1CA189867 (미국 NIH 보조금/계약)
- NCI-2022-05090 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- NRG-CC010 (기타 식별자: CTEP)
- NRG-CC010 (기타 식별자: NRG Oncology)
- NRG-CC010 (기타 식별자: DCP)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .